[Progress in cardiovascular protective effects of resveratrol].
Chen
Li-Na
LN
Zang
Wei-Jin
WJ
Tang
Yu-Hai
YH
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000517:prevention & control* / Q000628:therapy; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control* / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
D000975:Antioxidants; D002317:Cardiovascular Agents; D010975:Platelet Aggregation Inhibitors; D013267:Stilbenes; D014665:Vasodilator Agents; D000077185:Resveratrol